These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 7281107)

  • 21. Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
    Marongiu F; Mamusa AM; Mameli G; Conti M; Sorano GG; Biondi G; Farci P; Balestrieri A
    Ric Clin Lab; 1989; 19(2):157-63. PubMed ID: 2528202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays.
    Nossel HL; Butler VP; Wilner GD; Canfield RE; Harfenist EJ
    Thromb Haemost; 1976 Feb; 35(1):101-9. PubMed ID: 60791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Studies of the interractions of cyclamate with phenprocomon (author's transl)].
    Kinawi A; Baumgartl I
    J Clin Chem Clin Biochem; 1977 Jun; 15(6):345-8. PubMed ID: 894206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation.
    Rapold HJ
    Lancet; 1990 Feb; 335(8687):481-2. PubMed ID: 1968207
    [No Abstract]   [Full Text] [Related]  

  • 25. Fibrinopeptide A and intravascular coagulation in normotensive and hypertensive pregnancy and parturition.
    Wallmo L; Karlsson K; Teger-Nilsson AC
    Acta Obstet Gynecol Scand; 1984; 63(7):637-40. PubMed ID: 6516813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevention of sequelae after myocardial infarct. Results, methods and problems of a prospective multi-center study of the effect of acetylsalicylic acid, phenprocoumon and placebo].
    Breddin HK; Uberla KK
    Verh Dtsch Ges Inn Med; 1980; 86():1338-48. PubMed ID: 7013326
    [No Abstract]   [Full Text] [Related]  

  • 27. [Anticoagulants in tuberculostatic therapy].
    Bethge
    Dtsch Med Wochenschr; 1977 Apr; 102(15):590. PubMed ID: 849720
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy.
    Kyrle PA; Korninger C; Gössinger H; Glogar D; Lechner K; Niessner H; Pabinger I
    Thromb Haemost; 1985 Aug; 54(2):521-3. PubMed ID: 4082088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance characteristics of a simple radioimmunoassay for fibrinopeptide A.
    Walenga JM; Hoppensteadt D; Emanuele RM; Fareed J
    Semin Thromb Hemost; 1984 Oct; 10(4):219-27. PubMed ID: 6515418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship.
    Thijssen HH; Hamulyák K; Willigers H
    Thromb Haemost; 1988 Aug; 60(1):35-8. PubMed ID: 3187945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of the thrombin-antithrombin III complex in the diagnosis of pulmonary embolism and deep venous thrombosis--comparison with fibrinopeptide A, platelet factor 4 and beta-thromboglobulin].
    Blanke H; Praetorius G; Leschke M; Seitz R; Egbring R; Strauer BE
    Klin Wochenschr; 1987 Aug; 65(16):757-63. PubMed ID: 2958657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The concomitant use of suloctidil and a long-acting oral anticoagulant.
    Verhaeghe R; Vanhoof A
    Acta Clin Belg; 1977; 32(1):36-8. PubMed ID: 331824
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
    Haustein KO
    Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
    Breddin K; Loew D; Lechner K; Uberla K; Walter E
    Thromb Haemost; 1979 Feb; 41(1):225-36. PubMed ID: 483232
    [No Abstract]   [Full Text] [Related]  

  • 37. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
    Hofmann V; Ermanni M; Straub PW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1600. PubMed ID: 694497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A.
    Amiral J; Walenga JM; Fareed J
    Semin Thromb Hemost; 1984 Oct; 10(4):228-42. PubMed ID: 6393350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays.
    Pabinger I; Kyrle PA; Speiser W; Stoffels U; Jung M; Lechner K
    Thromb Haemost; 1990 Jun; 63(3):407-12. PubMed ID: 2402742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction.
    van Hulsteijn H; Kolff J; Briët E; van der Laarse A; Bertina R
    Am Heart J; 1984 Jan; 107(1):39-45. PubMed ID: 6197872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.